Forecast

Buy	4
Hold	0
Sell	0

News Go to news feed

Scipher Medicine merges with Chemomab in an all-stock transaction – valuation $150 million

Chemomab and Scipher Medicine are completing an all-stock transaction; the combined company will operate as Scipher Medicine and trade on NASDAQ under the ticker SCIP. Chemomab shareholders will receive about 32% and Scipher shareholders 68% of the diluted shares; the combined valuation is $150 million before a $30 million private placement. A consortium led by Northpond Ventures secures the $30 million financing, and liquidity is expected to extend into the second half of 2028. The goal is to advance Nebokitug (anti-CCL24) into a phase 2 trial for rheumatoid arthritis with top-line results expected in H1 2028; Dr. Reginald Seeto will be CEO, and Chemomab CEO Adi Mor will join the board. The transaction was unanimously approved by both boards and is expected to close in Q4 2026 after customary approvals. » More on de.investing.com
Chemomab Therapeutics: loss per share $0.32 in quarter ended Sept. 30, 2025

Chemomab Therapeutics released on Nov. 20, 2025 the results for the quarter ended Sept. 30, 2025. Loss per share was $0.32, compared with a loss of $0.80 in the year-ago quarter. No further financial figures were reported. » More on finanzen.net

Financials

In the last quarter, Chemomab Therapeutics ADR Aktie had revenue of €0 and net profit of -€1.93M

(EUR)	Jun 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-1.93M	10.56%
EBITDA	-2M	4.84%

Fundamentals

Metric	Value
Market capitalization	€14.05M
Number of shares	6.16M
52-week high/low	€3.08 - €1.16
Dividends	No
Beta	0.66
P/E ratio	-2.59
PEG ratio	-0.03
P/B ratio	2.44
P/S ratio	0.00

Company profile

Chemomab Therapeutics Ltd. ist ein in der klinischen Phase befindliches Biotech-Unternehmen, das Therapeutika zur Behandlung von Entzündungen und Fibrose erforscht und entwickelt. Der führende klinische Produktkandidat des Unternehmens ist CM-101, ein humanisierter monoklonaler Antikörper, der die grundlegende Funktion des löslichen Chemokins CCL24 für die Behandlung der primär sklerosierenden Cholangitis (PSC) und der systemischen Sklerose (SSc) hemmt. Das Unternehmen war früher als Anchiano Therapeutics Ltd. bekannt und änderte im März 2021 seinen Namen in Chemomab Therapeutics Ltd. Chemomab Therapeutics Ltd. wurde im Jahr 2011 gegründet und hat seinen Sitz in Tel Aviv, Israel.